$587.1 M

KURA Mkt cap, 11-Oct-2018
Kura Oncology Net income (Q2, 2018)-29.3 M
Kura Oncology Cash, 30-Jun-201817.7 M
Kura Oncology EV576.4 M

Kura Oncology Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

25.1m

General and administrative expense

9.4m

Operating expense total

36.1m

Interest expense

888.0k

Interest income

751.0k

Net Income

(27.6m)(35.4m)

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

3.3m3.0k3.6m4.0m4.3m5.2m5.2m11.3m22.4m

General and administrative expense

1.5m63.0k2.4m1.8m1.7m2.1m2.2m3.4m7.1m

Operating expense total

5.9m66.0k7.0m6.8m7.1m7.7m7.9m9.5m15.0m30.3m

Interest expense

42.0k42.0k42.0k189.0k194.0k203.0k209.0k226.0k258.0k525.0k

Interest income

22.0k38.0k114.0k124.0k131.0k128.0k124.0k197.0k450.0k1.1m

Net Income

(5.6m)(66.0k)(6.6m)(6.7m)(6.9m)(7.5m)(7.8m)(9.3m)(14.6m)(29.3m)

Kura Oncology Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

6.6k5.6k15.4m9.7m11.4m

Accounts Receivable

92.4m

Inventories

693.0k725.0k

Current Assets

86.9m68.8m94.6m

PP&E

71.0k40.0k10.0k

Total Assets

9.1k5.6k87.3m69.8m95.9m

Accounts Payable

350.02.4k4.1m4.7m8.3m

Short-term debt

1.5m

Current Liabilities

5.1m5.5m10.0m

Long-term debt

5.6m

Total Debt

7.1m

Total Liabilities

12.9m16.0m

Additional Paid-in Capital

49.5k49.5k108.5m110.7m169.2m

Retained Earnings

(26.3m)(53.9m)(89.3m)

Total Equity

(124.0k)(154.7k)82.1m56.9m79.9m

Financial Leverage

-0.1 x0 x1.1 x1.2 x1.2 x

Quarterly

USDQ3, 2017Q1, 2018Q2, 2018

Cash

26.5m17.7m

Inventories

909.0k

Current Assets

140.4m128.5m

PP&E

5.0k1.0k

Total Assets

141.5m129.6m

Accounts Payable

6.2m8.7m9.3m

Short-term debt

2.3m2.8m

Current Liabilities

11.4m12.6m

Long-term debt

4.9m4.2m

Total Debt

7.2m7.0m

Total Liabilities

16.7m17.2m

Additional Paid-in Capital

228.8m231.1m

Retained Earnings

(103.9m)(118.6m)

Total Equity

124.8m112.4m

Financial Leverage

1.1 x1.2 x

Kura Oncology Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.6k)(30.7k)(3.7m)(27.6m)(35.4m)

Depreciation and Amortization

1.0k31.0k30.0k

Accounts Receivable

Inventories

(42.0k)(32.0k)

Accounts Payable

(1.5k)2.1k833.0k471.0k3.6m

Cash From Operating Activities

(23.2k)(16.0k)(849.0k)(25.3m)(28.4m)

Purchases of PP&E

(28.0k)(64.0k)

Cash From Investing Activities

(28.0k)12.2m(23.4m)

Cash From Financing Activities

25.0k15.0k2.0m7.5m53.6m

Interest Paid

352.0k627.0k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(5.6m)(66.0k)(6.6m)(6.7m)(6.9m)(7.5m)(9.3m)

Inventories

909.0k

Accounts Payable

650.0713.08.2k10.7k2.5m3.7m3.1m3.3m4.2m3.7m4.2m6.2m

Kura Oncology Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information

Kura Oncology Operating Metrics

FY, 2016

Phase II Trials Products

1

Preclinical Phase Products

2
Report incorrect company information